Maryland Heights, MO, March 30, 2017 --(PR.com
)-- The global liver diseases therapeutic drugs market is estimated to reach USD 11.5 Billion in 2020, expanding at a CAGR of 6.2% from 2016 to 2020, due to unmet need and chronic liver cancer and hepatitis incidences worldwide.
Browse Liver Diseases Therapeutic Drugs Market by Drug Classes (Antiviral, Chemotherapy, Corticosteroids, Immunoglobulins, Immunosupressants, Targeted Therapy Drugs and Vaccines), and Therapeutic Applications (Alcohol Induced Liver Diseases, Autoimmune Liver Disorders, Hepatocellular Carcinoma, NAFLD, Viral or Hepatitis Liver Disorders) 2016-2020 at https://www.ihealthcareanalyst.com/report/liver-diseases-therapeutics-market/
Liver diseases and disorders that cause the liver to function improperly or cease functioning and it is a major problem of worldwide proportions. Liver disease in general can be termed as the abnormal functioning of liver, which can be due to excessive alcohol consumption or a viral infection. Liver disease may have complex effects on drug clearance, biotransformation, and pharmacokinetics. Pathogenetic factors include alterations in intestinal absorption, plasma protein binding, hepatic extraction ratio, liver blood flow, portal-systemic shunting, biliary excretion, enterohepatic circulation, and renal clearance. Aging population increasing prevalence of liver diseases such as hepatitis and liver cancer coupled with elevated demand for vaccination programs and increasing healthcare-related consumer expenditure are driving the growth of global liver diseases therapeutic drugs market.
The global liver diseases therapeutic drugs market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes (antiviral, chemotherapy, Corticosteroids, immunoglobulins, immunosupressants, targeted therapy drugs and vaccines), therapeutic applications (alcohol induced liver diseases, autoimmune liver disorders, hepatocellular carcinoma, NAFLD, viral or hepatitis liver disorders), and forecasts growth trends (CAGR% - 2016 to 2020). The global liver diseases therapeutic drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global liver diseases therapeutic drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global liver diseases therapeutic drugs market and included in this report are Abbott Laboratories Astellas Pharma Inc, Gilead Science Inc, Merck & Co., Bristol-Myers Squibb, Novartis, Pfizer and F. Hoffmann-La Roche Ltd.
To request Table of Contents and Sample Pages of this report visit:
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043